Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBT (2016 - 2025)

United Therapeutics' EBT history spans 17 years, with the latest figure at $444.0 million for Q4 2025.

  • For Q4 2025, EBT rose 11.98% year-over-year to $444.0 million; the TTM value through Dec 2025 reached $1.7 billion, up 11.36%, while the annual FY2025 figure was $1.7 billion, 11.36% up from the prior year.
  • EBT for Q4 2025 was $444.0 million at United Therapeutics, up from $438.0 million in the prior quarter.
  • Across five years, EBT topped out at $444.0 million in Q4 2025 and bottomed at $32.5 million in Q1 2021.
  • The 5-year median for EBT is $323.8 million (2022), against an average of $303.6 million.
  • The largest annual shift saw EBT tumbled 81.06% in 2021 before it soared 849.85% in 2022.
  • A 5-year view of EBT shows it stood at $140.5 million in 2021, then grew by 27.26% to $178.8 million in 2022, then surged by 65.21% to $295.4 million in 2023, then surged by 34.22% to $396.5 million in 2024, then rose by 11.98% to $444.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's EBT are $444.0 million (Q4 2025), $438.0 million (Q3 2025), and $408.4 million (Q2 2025).